Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ: NVAX )

7.470 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,297
Open 7.470
Bid (Size) 7.370 (1)
Ask (Size) 7.470 (1)
Prev. Close 7.470
Today's Range 7.470 - 7.470
52wk Range 3.900 - 23.86
Shares Outstanding 74,484,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision. 
Via Benzinga
Exposures COVID-19 Product Safety
Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday
Via Benzinga

Performance

YTD
-12.84%
-12.84%
1 Month
-2.86%
-2.86%
3 Month
-15.40%
-15.40%
6 Month
-25.30%
-25.30%
1 Year
+78.28%
+78.28%

More News

Read More
Novavax Signals Chances Of FDA Approval For Its COVID-19 Vaccine: But Retail Sentiment Wavers
Via Stocktwits
Topics Government
Exposures COVID-19 Political Product Safety
Earnings Scheduled For February 27, 2025
Via Benzinga
(NVAX) - Analyzing Novavax's Short Interest
Via Benzinga
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study
Via Benzinga
Exposures COVID-19
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling
Via Stocktwits
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
Via Chartmill
2 Beaten-Down Stocks That Still Aren't Worth Buying
Via The Motley Fool
Topics Cannabis Government Law Enforcement
Exposures Cannabis Legal Political
Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
Via Benzinga
Topics World Trade
Exposures Product Safety Tariff
Novavax Vaccine Approval From FDA In Limbo, Says Report – But Retail Is Hopeful
Via Stocktwits
Exposures COVID-19 Product Safety
FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine
Via Benzinga
Exposures COVID-19 Product Safety
Moderna, Novavax Shares Are Tumbling Monday: What's Going On?
Via Benzinga
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Via Investor's Business Daily
Exposures Product Safety
Moderna, Novavax Shares Are Sliding Wednesday: What's Going On?
Via Benzinga
Topics Government
Exposures Political
2 Beaten-Down Stocks Near Their 52-Week Lows That Aren't Worth Buying
Via The Motley Fool
Nvidia, Tesla Lead Tech Stock Rebound: What's Driving Markets Friday?
Via Benzinga
1 Biotech Stock to Buy in 2025, and 1 to Avoid
Via The Motley Fool
Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership
Via Stocktwits
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Via Benzinga
Exposures COVID-19
Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples
Via Stocktwits
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch
Via Benzinga
Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?
Via Benzinga
Topics Government
Exposures Political
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
Via Investor's Business Daily
Exposures COVID-19
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.